A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. - Wikidata - awgldk - TriplyDB

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

http://www.wikidata.org/entity/Q33439342

about

Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Advances of small molecule targeting of kinases.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.

P2860

Q38660811-5744740F-4723-463A-89F9-8759B9B5D9DE Q39450797-3C2C8643-0D9D-4725-8D8E-B8635452D279 Q47130816-0ECAE8F7-B1E6-4D41-ABE9-BC3F6453EF13

P2860

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

http://www.wikidata.org/entity/Q33439342

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

A phase II study to evaluate L ...... in pancreatic cancer patients.

@ast

A phase II study to evaluate L ...... in pancreatic cancer patients.

@en

type

label

A phase II study to evaluate L ...... in pancreatic cancer patients.

@ast

A phase II study to evaluate L ...... in pancreatic cancer patients.

@en

prefLabel

A phase II study to evaluate L ...... in pancreatic cancer patients.

@ast

A phase II study to evaluate L ...... in pancreatic cancer patients.

@en

P1433

Q33439342-B043BF64-ADC2-492F-BFC2-991C3F72D54E

P1476

Q33439342-10C9D654-48D2-4733-B982-390D1F9E0832

P2093

Q33439342-0074BEB6-31E9-4015-8342-D4CB6D7E27D5

Q33439342-2D7222B0-13EA-4DDE-AEEB-56444F0E5709

Q33439342-3058F866-3744-4546-824C-81BBC020E027

Q33439342-31AC970B-AE8F-4B63-88CF-3A82CEBAC02D

Q33439342-4593BB89-3C74-4BF1-9AD6-91B0B4946DEF

Q33439342-485C8E2C-B392-49A3-B368-E35569377123

Q33439342-56273580-2D67-429F-8313-035621EE9D8C

Q33439342-7BD92E5B-24BF-4672-9AF2-EBB5F1313055

Q33439342-82381C5A-A06F-47F9-B1A5-3EBE86656F5D

Q33439342-886804AF-E7E9-42FB-AE5C-12C5DCECD51F

P2860

Q33439342-02A0C4C3-2E92-4E3F-B79C-2D442168C6D1

Q33439342-1E218CD4-B7CC-4866-88CA-F1B3AEA63453

Q33439342-235C4641-4A93-4588-A8D4-94D181131FE3

Q33439342-247D8C85-691A-42FC-ACA0-C9444E4C2D42

Q33439342-3E08D92F-E9AE-4230-8B10-BF88C0BBF043

Q33439342-46AA2AE9-772E-4DBA-B01E-B66033AD67CC

Q33439342-4AC39C0A-4D12-45DC-A886-A56D1994342E

Q33439342-56E0C4E7-3054-44F1-B503-3090FB58C13A

Q33439342-57D57558-9ADB-40C4-B082-F724FFC7BEAE

Q33439342-61E13A48-D513-4D87-B593-EF134831ABAA

P2888

Q33439342-1CAD67E6-87A9-434B-A07E-74F67815B822

P304

Q33439342-2070EBB3-7C12-4F83-B387-BA8E981B7799

P31

Q33439342-E2EE52C0-AC59-4DB7-844C-8A9EF588303D

P356

Q33439342-69944D2A-EBE6-409F-9A51-F8C6D2B7BF8B

P407

Q33439342-D179FD59-160D-47DA-B56F-0391731AAB7F

P433

Q33439342-8DB37BFD-5436-46F8-A44C-56946AC7E710

P478

Q33439342-BF5E780A-654C-409C-A6EF-EC46C0FD699F

P50

Q33439342-573D5FAC-69FA-4197-B8B1-22B96906C700

Q33439342-5D92F3CD-55E9-4958-9809-4FC399797AF3

P577

Q33439342-9E806A46-6D76-4764-81AB-4AE4C18DE205

P6179

Q33439342-970864A1-B302-461B-85F0-DB99462EDAE1

P698

Q33439342-17ADD7C7-07D6-461C-8749-A814332FA4D1

P932

Q33439342-1116703E-260F-4D74-8B95-AF4D696AFD2C

P356

S12885-017-3131-X

P1433

P1476

A phase II study to evaluate L ...... in pancreatic cancer patients

@en

P2093

Aimee Bence Lin

http://www.w3.org/2001/XMLSchema#string

Berta Laquente

http://www.w3.org/2001/XMLSchema#string

Cezary Szcylik

http://www.w3.org/2001/XMLSchema#string

Daniel Von Hoff

http://www.w3.org/2001/XMLSchema#string

David Z Chang

http://www.w3.org/2001/XMLSchema#string

Dirk Richel

http://www.w3.org/2001/XMLSchema#string

Donald Richards

http://www.w3.org/2001/XMLSchema#string

Emiliano Calvo

http://www.w3.org/2001/XMLSchema#string

G L Frassineti

http://www.w3.org/2001/XMLSchema#string

George Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

New challenges in perioperative management of pancreatic cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

P2888

s12885-017-3131-x

P304

137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3131-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Cascinu

J A López-Martin

P577

2017-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083821486

http://www.w3.org/2001/XMLSchema#string

P698

28202004

http://www.w3.org/2001/XMLSchema#string

P932

5312529

http://www.w3.org/2001/XMLSchema#string